TYVASO DPI IS NOW APPROVED

Learn more
Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

SELECT INDICATION
Search Button
Skip to main content
FOR US HEALTHCARE PROFESSIONALS ONLY
logo
logo
SELECT INDICATION

ABOUT PH-ILD

WHAT IS TYVASO?

CLINICAL STUDIES

STARTING TYVASO

RESOURCES & SUPPORT

Site map

HOME

ABOUT PH-ILD

Screening

Impact

Prevalence

WHAT IS TYVASO?

Direct to Lungs

FAQs

CLINICAL STUDIES

INCREASE Study Overview

INCREASE Results

INCREASE Safety

BREEZE Study

STARTING TYVASO

TYVASO DPI

TYVASO Nebulizer

Dosing & Titration

Reaching Target Dose

Managing AEs

RESOURCES & SUPPORT

HCP Support

Patient Support

Resource Library

REQUEST A REP

PRESCRIBING INFORMATION

TYVASO

TYVASO DPI

INSTRUCTIONS FOR USE

TYVASO

TYVASO DPI

REFERRAL FORM

PATIENT SITE

AE=adverse event; DPI=dry powder inhaler.

The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.

CLOSE

Yes, I am a US healthcare professional and would like to continue.